卵巣がんとホルモン置換療法"百万女性研究"
1Million Women Study Coordinating Centre, Cancer Research UK Epidemiology Unit, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK. pa.valerie.beral@ceu.ox.ac.uk
Lancet (London, England)
|May 22, 2007
まとめ
ホルモン置換療法 (HRT) を使用している女性は,卵巣がんを発症し,卵巣がんで死亡するリスクが高くなります. この研究では,HRTの使用が1991年以来,英国で約1300件の卵巣がんと1000件の死亡につながったことが判明しました.
科学分野:
- 腫瘍学 腫瘍学
- エピデミオロジー エピデミオロジー
- 婦人科 婦人科について
背景:
- 卵巣がんは,英国の女性にとって重要な健康上の問題であり,最も一般的な癌の4番目にあります.
- ホルモン置換療法 (HRT) の使用に関連した卵巣がんの特定のリスクに関するデータは限られている.
研究 の 目的:
- ホルモン置換療法 (HRT) の使用と卵巣がんを発症し死亡するリスクとの関連を調査する.
- 卵巣がんのリスクを定量化するために,現在のおよび過去のHRTユーザーを,決してユーザと比較して.
主な方法:
- イギリスの百万女性研究から948,576人の閉経後の女性を対象とした大規模なコホート研究です.
- 発生卵巣がんの追跡期間は平均5.3年,死亡率は6.9年であり,HRTの使用データは収集され,更新されました.
- 相対的なリスクは計算され,年齢と子宮切除の状態によって層分化され,複数の混同要因に調整されました.
主要な成果:
- 現在HRTを使用している女性は,これまで使用していない女性と比較して,卵巣がんを発症する (RR 1.20) と卵巣がんで死亡する (RR 1.23) のリスクが著しく高まっていることが示されました.
- 卵巣がんのリスクは,HRTの使用期間が長くなるにつれて増加し,異なる腫瘍組織学,特に血清性上皮質腫瘍のリスクが高くなる変化が観察されました.
- 過去のHRT使用者は卵巣がんのリスク増加を示さなかった (RR 0.98 発生率,0.97 死亡率).
結論:
- ホルモン置換療法 (HRT) の使用は,発生性および致死性卵巣がんのリスクの増加と関連しています.
- この研究は,HRTの使用が1991年以来,英国で約1300件の卵巣がんの追加症例と1000件の死亡に寄与したと推定しています.
関連する概念動画
Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

